Maxim Group Reiterates Bullish View on Inovio (INO) as Zika Vaccine Moves Closer to Human Trials
Tweet Send to a Friend
Maxim Group analyst Jason McCarthy reiterated a Buy rating and $14 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
